Pila Pharma AB (PILA)

Overview

PILA PHARMA AB (publ) is a pioneering clinical stage pharmaceutical company situated in Malmö, Sweden, dedicated to the research and development of innovative treatments for type 2 diabetes. Established in 2014, the company has carved out a niche for itself in the pharmaceutical industry by focusing on the development of novel therapeutic agents that target TRPV1 antagonists—a class of compounds with significant potential in diabetes management. Its drive to innovate and commitment to addressing the complex challenges of type 2 diabetes underscores PILA PHARMA's role in the evolving landscape of diabetes care.

Products and Services

PILA PHARMA AB is at the forefront of developing groundbreaking products aimed at improving the lives of people living with type 2 diabetes. The focus of their research and development efforts is XEN-D0501, a proprietary compound that showcases the company's innovation in pharmaceuticals.

• XEN-D0501: A novel TRPV1 antagonist which has successfully completed two phase 2b clinical trials. This product represents PILA PHARMA's commitment to offering new therapeutic options for managing type 2 diabetes. By targeting the TRPV1 receptors, XEN-D0501 aims to provide a unique mechanism of action in the modulation of pain and inflammation response, concepts that are increasingly recognized as significant in the pathogenesis of diabetes. The successful progression of XEN-D0501 through clinical trials underscores PILA PHARMA’s capability to carry promising compounds through the demanding pharmaceutical development pipeline, with the ultimate goal of delivering safe and effective new treatments to patients.